INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG
   C/O HORIZON PHARMA, INC.
   1033 SKOKIE BLVD., SUITE 355
   NORTHBROOK IL 60062

2. Date of Event Requiring Statement
   07/28/2011

3. Issuer Name and Ticker or Trading Symbol
   HORIZON PHARMA, INC. [HZNP]

4. Relationship of Reporting Person(s) to Issuer
   Director
   X 10% Owner
   Officer (give title below)

5. If Amendment, Date of Original Filed

6. Individual or Joint/Group Filing (Check Applicable Line)
   Form filed by One Reporting Person
   X
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Amount of Securities Beneficially Owned</th>
<th>Ownership Form</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>51,731</td>
<td>D (1)</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>71,556</td>
<td>D (2)</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Date Exercisable</th>
<th>Date Expiration</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Ownership Form</th>
<th>Nature of Indirect Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series A Preferred Stock</td>
<td>(3)</td>
<td>(3)</td>
<td>Common Stock</td>
<td>401,927</td>
<td>(3)</td>
<td>D (1)</td>
<td></td>
</tr>
<tr>
<td>Series A Preferred Stock</td>
<td>(3)</td>
<td>(3)</td>
<td>Common Stock</td>
<td>555,956</td>
<td>(3)</td>
<td>D (2)</td>
<td></td>
</tr>
<tr>
<td>Series B Preferred Stock</td>
<td>(3)</td>
<td>(3)</td>
<td>Common Stock</td>
<td>44,364</td>
<td>(3)</td>
<td>D (1)</td>
<td></td>
</tr>
<tr>
<td>Series B Preferred Stock</td>
<td>(3)</td>
<td>(3)</td>
<td>Common Stock</td>
<td>61,366</td>
<td>(3)</td>
<td>D (2)</td>
<td></td>
</tr>
<tr>
<td>Convertible Promissory Notes</td>
<td>(4)</td>
<td>(4)</td>
<td>Common Stock</td>
<td>805,856.5</td>
<td>(4)</td>
<td>D (1)</td>
<td></td>
</tr>
<tr>
<td>Convertible Promissory Notes</td>
<td>(4)</td>
<td>(4)</td>
<td>Common Stock</td>
<td>114,665.38</td>
<td>(4)</td>
<td>D (2)</td>
<td></td>
</tr>
</tbody>
</table>

1. Name and Address of Reporting Person
   NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG
   C/O HORIZON PHARMA, INC.
   1033 SKOKIE BLVD., SUITE 355
   NORTHBROOK IL 60062
1. Name and Address of Reporting Person

NGN BioMed Opportunity I L P

<table>
<thead>
<tr>
<th>(Last)</th>
<th>(First)</th>
<th>(Middle)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C/O HORIZON PHARMA, INC.</td>
<td>1033 SKOKIE BLVE., SUITE 355</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(Street)</th>
<th>(City)</th>
<th>(State)</th>
<th>(Zip)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORTHBROOK</td>
<td>IL</td>
<td>60062</td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. Securities held in the name of NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG.
2. Securities held in the name of NGN Biomed Opportunity I, L.P.
3. The shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Every 2.374 shares of preferred stock will automatically convert into one share of common stock upon the closing of the Issuer's initial public offering.

Every 2.374 shares of preferred stock will automatically convert into one share of common stock upon the closing of the Issuer's initial public offering.

4. Principal and accrued interest will convert upon the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the lesser of (i) the public offering price of the Common Stock sold in the Issuer's initial public offering, or (ii) $18.92. Amounts shown are reported in US dollars and include interest accrued through the date hereof; additional interest will accrue prior to conversion.

/s/ See Exhibit 99.1 07/28/2011

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* if the form is filed by more than one reporting person, see Instruction 5 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Signature of Reporting Persons:

This statement on Form 4 is filed by NGN BIOMED OPPORTUNITY I, L.P. and NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS. The principal business address of NGN BIOMED OPPORTUNITY I, L.P. is 369 LEXINGTON AVENUE, 17TH FLOOR, NEW YORK, NEW YORK 10017, and the principal business address of NGN BIOMED OPPORTUNITY I GMBH & CO BETEILIGUNGS KG is BERGHEIMER STRASSE 89A, HEIDELBERG, GERMANY. The reporting persons disclaim beneficial ownership of the securities listed herein except to the extent of their pecuniary interest therein.

NGN BIOMED OPPORTUNITY I, L.P.

By: NGN BIOMED I GP, L.P., its general partner

   By: NGN CAPITAL, LLC, its general partner

      By: /s/ John R. Costantino

      Name: John R. Costantino

      Title: Manager

NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG

By: NGN CAPITAL, LLC, its managing limited partner

   By: /s/ John R. Costantino

      Name: John R. Costantino

      Title: Manager